Randomized Study on the Effect of Oesophageal Temperature on the Incidence of Esophageal Lesions After AF Ablation
A Prospective Randomized Study on the Effect of Oesophageal Temperature Monitoring on the Incidence of Esophageal Lesions After Left Atrial Ablation for the Treatment of Atrial Fibrillation.
1 other identifier
interventional
60
1 country
1
Brief Summary
It's a randomized pilot study to evaluate the incidence of esophageal thermal injury after left atrial ablation for the treatment of atrial fibrillation according to three different strategies of esophageal temperature monitoring. These patients will be divided into 3 groups with different strategies of esophageal temperature monitoring: group 1 without monitoring, group 2 monitoring with single probe thermometer and group 3 monitoring with multi-probe thermometer. The primary end point will be the incidence of esophageal lesions assessed by upper endoscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 11, 2017
CompletedFirst Submitted
Initial submission to the registry
August 22, 2018
CompletedFirst Posted
Study publicly available on registry
August 24, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
July 24, 2020
CompletedJanuary 10, 2022
January 1, 2022
1.2 years
August 22, 2018
January 6, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of esophageal lesions
Incidence of esophageal lesions evaluated by upper digestive endoscopy
Within three days after the ablation procedure.
Secondary Outcomes (7)
Rate of recurrence of AF
Six months
Isolation rate of pulmonary veins at the end of ablation.
End of the procedure
Duration of the AF ablation procedure
End of the procedure
Incidence of atrio-esophageal fistulas
Six months
Difference in the size of the esophageal lesions
Within three days
- +2 more secondary outcomes
Study Arms (3)
No probe
NO INTERVENTIONTwenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
Single probe thermometer
ACTIVE COMPARATORTwenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
Multi-probe
ACTIVE COMPARATORTwenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
Interventions
Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
Eligibility Criteria
You may qualify if:
- Patients with paroxysmal or persistent AF, diagnosed by electrocardiogram, 24-hour Holter, or monitors of implantable or non-implantable events, with at least one episode of AF up to 12 months before the procedure. Patients should be willing and able to sign an informed consent form, and to undergo all procedures described in both the study protocol and the consent form.
You may not qualify if:
- Atrial thrombus in the left atrium, history of AF ablation, history of cardiac surgery, contraindication to anticoagulation, permanent AF, New York Heart Association functional class III or IV, stroke in the last 3 months, pregnancy, history blood clotting abnormalities, previous oesophageal surgery, or advanced chronic kidney disease (creatinine \> 2.5 mg/dl).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Sao Paulo General Hospitallead
- Circa Scientific, Inc.collaborator
Study Sites (1)
Arrhythmia Clinical Unit - Instituto do Coração - HCFMUSP
São Paulo, São Paulo, 05403010, Brazil
Related Publications (1)
Moura DMC, Pereira RAR, Pisani CF, Wu TC, Chokr MO, Hardy CA, Melo SL, Darrieux FCDC, Hachul DT, Scanavacca MI. Esophageal Temperature Monitoring during Atrial Fibrillation Ablation: A Randomized Study. Arq Bras Cardiol. 2025 Jun;122(7):e20250056. doi: 10.36660/abc.20250056. English, Portuguese.
PMID: 40767688DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mauricio I Scanavacca, MD, PhD
Instituto do coração - HC/FMUSP
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Arrhythmia Clinical Unit Director
Study Record Dates
First Submitted
August 22, 2018
First Posted
August 24, 2018
Study Start
July 11, 2017
Primary Completion
October 1, 2018
Study Completion
July 24, 2020
Last Updated
January 10, 2022
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will not share